On March 31, 2025, HCW Biologics Inc. stockholders approved a reverse stock split at a ratio of one-for-forty, effective April 11, 2025, to maintain its Nasdaq listing. Additionally, stockholders approved an equity line of credit and the conversion of $6.9 million in senior secured notes into shares.